J&J, Pharmacyclics add Diplomat to limited distribution network for Imbruvica
FLINT, Mich. — Diplomat has joined the limited distribution network for a rare form of blood cancer drug marketed by Johnson & Johnson and Pharmacyclics.
The specialty pharmacy said Thursday that J&J subsidiary Janssen Biotech and Pharmacyclics had added it to the limited distribution network for Imbruvica (ibrutinib), which the Food and Drug Administration approved this week for mantle cell lymphoma.
"We are pleased to partner with Pharmacyclics and Janssen Biotech Inc. as a specialty pharmacy provider of Imbruvica," Diplomat president Gary Kadlec said. "Diplomat has proven expertise in handling limited distribution drugs and an industry-wide reputation for comprehensive patient care outreach that improves patient compliance, adherence and outcomes."
New HIV treatment guidelines call for more vaccinations and chronic disease testing, treatment
ARLINGTON, Va. — Antiretroviral drugs have allowed people with HIV to live normal life spans, but because of this, they also are susceptible to many new health complications, according to care guidelines released Thursday by the Infectious Diseases Society of America.
The IDSA’s HIV Medicine Association said that people with HIV have an increased risk for such common health conditions as high cholesterol and triglycerides, which can result from the infection itself, antiretroviral drug treatment or traditional risk factors like smoking and unhealthy diets. The longer lifespans of HIV patients, with an estimated 80% of patients having the virus under control, mean doctors should be more vigilant, according to the group.
"This means that HIV specialists need to provide the full spectrum of primary care to these patients, and primary care physicians need a better grasp of the impact HIV care has on routine health care," lead author of the guidelines and New York University researcher Judith Aberg said. "Doctors need to tell their HIV-infected patients, ‘Your HIV disease is controlled, and we need to think about the rest of you.’ As with primary care in general, it’s about prevention."
In particular, the guidelines include new recommendations for screening for diabetes, osteoporosis, colon cancer and sexually transmitted diseases, as well as vaccinations against pneumococcal infection, influenza, varicella and hepatitis A and B. They also include information outlining interactions between specific antiretrovirals and cholesterol-lowering statins.
Avella Specialty Pharmacy joins limited distribution network for Imbruvica
PHOENIX — Drug makers Johnson & Johnson and Pharmacyclics have added Avella Specialty Pharmacy to their limited-distribution network for a newly approved blood cancer drug.
Avella said Thursday that it had joined the limited-distribution network for Imbruvica (ibrutinib), which the Food and Drug Administration approved this week for mantle cell lymphoma. Avella is one of five specialty pharmacies to join the network, the company said.
"We are proud to be a specialty pharmacy provider of Imbruvica capsules, now approved by the FDA for the treatment of patients with MCL," Avella VP business development Leslie Yendro said. "Avella has the ability to serve patients in all 50 states and to provide high-touch patient services and reliable product data to ensure maximum drug effectiveness."